Kura Oncology KURA Ziftomenib — Research And Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Kura Oncology in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kura Oncology's ziftomenib — research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kura Oncology's ziftomenib — research and development expense?
- Kura Oncology (KURA) reported ziftomenib — research and development expense of $36.88M in Q1 2026.
- How has Kura Oncology's ziftomenib — research and development expense changed year-over-year?
- Kura Oncology's ziftomenib — research and development expense increased by 23.2% year-over-year, from $29.95M to $36.88M.
- What is the long-term trend for Kura Oncology's ziftomenib — research and development expense?
- Over 3 years (2022 to 2025), Kura Oncology's ziftomenib — research and development expense has grown at a 89.2% compound annual growth rate (CAGR), from $21.07M to $142.58M.
- What does ziftomenib — research and development expense mean?
- This metric represents the total operating costs directly attributable to the research, clinical development, and regulatory advancement of the specific drug candidate. It captures the investment intensity required to progress the asset through clinical trials and pre-commercialization phases. Monitoring this expenditure helps investors assess the company's capital allocation strategy and the pace of development for its core pipeline assets.